Local increase of arginase activity in lesions of patients with cutaneous leishmaniasis in ethiopia

PLoS Neglected Tropical Diseases

Volumn 6, Issue 6, 2012, Pages

  Abebe, Tamrat ^a,b   Hailu, Asrat ^a   Woldeyes, Mihretu ^a   Mekonen, Woinshet ^a   Bilcha, Kassahun ^c   Cloke, Thomas ^d   Fry, Lionel ^d   Seich al Basatena, Nafisa Katrin ^d   Corware, Karina ^d   Modolell, Manuel ^e   Munder, Markus ^f   Tacchini Cottier, Fabienne ^b   Müller, Ingrid ^d   Kropf, Pascale ^g  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF GONDAR   (Ethiopia)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGININE; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ENZYME ACTIVITY; ETHIOPIA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCHOOL CHILD; SKIN BIOPSY; SKIN LEISHMANIASIS; T LYMPHOCYTE; BIOPSY; CHEMISTRY; ENZYMOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; SKIN;

ADOLESCENT; ADULT; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; ARGINASE; BIOPSY; CHILD; ETHIOPIA; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SKIN; YOUNG ADULT;

EID: 84863678194     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001684     Document Type: Article

References (62)

1. WHO (2004) The World health report 2004. Available: http://www.who.int/whr/2004/en. Accessed 2012 May 7.
2. WHO (2006) Control of leishmaniasis. Report by the Secretariat. Available: https://apps.who.int/gb/ebwha/pdf_files/EB118/B118_4-en.pdf. Accessed 2012 May 7.
3. WHO (2010) Control of the leishmaniases. Available: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf. Accessed 2012 May 7.
4. Hailu A, Gramiccia M, Kager PA, (2009) Visceral leishmaniasis in Aba-Roba, south-western Ethiopia: prevalence and incidence of active and subclinical infections. Ann Trop Med Parasitol 103: 659-670.
5. Morrone A, Pitidis A, Pajno MC, Dassoni F, Latini O, et al. (2011) Epidemiological and geographical aspects of leishmaniasis in Tigray, northern Ethiopia: a retrospective analysis of medical records, 2005-2008. Trans R Soc Trop Med Hyg 105: 273-280.
6. Negera E, Gadisa E, Yamuah L, Engers H, Hussein J, et al. (2008) Outbreak of cutaneous leishmaniasis in Silti woreda, Ethiopia: risk factor assessment and causative agent identification. Trans R Soc Trop Med Hyg 102: 883-890.
7. Lemma A, Foster WA, Gemetchu T, Preston PM, Bryceson A, et al. (1969) Studies on leishmaniasis in Ethiopia. I. Preliminary investigations into the epidemiology of cutaneous leishmaniasis in the highlands. Ann Trop Med Parasitol 63: 455-472.
8. Sarojini PA, Humber DP, Yemane-Berhan T, Fekete E, Belehu A, et al. (1984) Cutaneous leishmaniasis cases seen in two years at the All Africa Leprosy and Rehabilitation Training Centre Hospital. Ethiop Med J 22: 7-11.
9. Mengistu G, Laskay T, Gemetchu T, Humber D, Ersamo M, et al. (1992) Cutaneous leishmaniasis in south-western Ethiopia: Ocholo revisited. Trans R Soc Trop Med Hyg 86: 149-153.
10. Berhe N, Balkew M, Gebre-Michael T, Ali A, Hailu A, (1998) Leishmaniasis in the middle course of the Ethiopian Rift Valley: I. Clinical and leishmanin skin test surveys. Ethiop Med J 36: 113-122.
11. Lemma W, Erenso G, Gadisa E, Balkew M, Gebre-Michael T, et al. (2009) A zoonotic focus of cutaneous leishmaniasis in Addis Ababa, Ethiopia. Parasit Vectors 2: 60.
12. Hailu A, Gebre-Michael T, Berhe N, Balkew M, (2005) Leishmaniasis. In: Yemane Berhane DHM, Helmut Kloos, editors. Epidemiology and Ecology of health and disease in Ethiopia Shama Books.
13. Bryceson A, Foster WA, Lemma A, (1969) Clinical trial of CI-501 (Camolar) against cutaneous leishmaniasis in Ethiopia. Trans R Soc Trop Med Hyg 63: 152-153.
14. Kaye P, Scott P, (2011) Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 9: 604-615.
15. Mougneau E, Bihl F, Glaichenhaus N, (2011) Cell biology and immunology of Leishmania. Immunol Rev 240: 286-296.
16. Sacks DL, Noben-Trauth N, (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nature Reviews Immunol 2: 845-858.
17. Childs GE, Lightner LK, McKinney L, Groves MG, Price EE, et al. (1984) Inbred mice as model hosts for cutaneous leishmaniasis. I. Resistance and susceptibility to infection with Leishmania braziliensis, L. mexicana, and L. aethiopica. Ann Trop Med Parasitol 78: 25-34.
18. Akuffo HO, Walford C, Nilsen R, (1990) The pathogenesis of Leishmania aethiopica infection in BALB/c mice. Scand J Immunol 32: 103-110.
19. Humber DP, Hetherington CM, Atlaw T, Eriso F, (1989) Leishmania aethiopica: infections in laboratory animals. Exp Parasitol 68: 155-159.
20. Bryceson AD, (1970) Diffuse cutaneous leishmaniasis in Ethiopia. 3. Immunological studies. IV. Pathogenesis of diffuse cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 64: 380-393.
21. Akuffo H, Maasho K, Blostedt M, Hojeberg B, Britton S, et al. (1997) Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-gamma. J Infect Dis 175: 737-741.
22. Schurr E, Kidane K, Yemaneberhan T, Wunderlich F, (1986) Cutaneous leishmaniasis in Ethiopia: I. Lymphocyte transformation and antibody titre. Trop Med Parasitol 37: 403-408.
23. Maasho K, Sanchez F, Schurr E, Hailu A, Akuffo H, (1998) Indications of the protective role of natural killer cells in human cutaneous leishmaniasis in an area of endemicity. Infect Immun 66: 2698-2704.
24. Bronte V, Zanovello P, (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654.
25. Rodriguez PC, Ochoa AC, (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222: 180-191.
26. Munder M, (2009) Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 158: 638-651.
27. Fu H, Khan A, Coe D, Zaher S, Chai JG, et al. (2011) Arginine depletion as a mechanism for the immune privilege of corneal allografts. Eur J Immunol 41: 2997-3005.
28. Kropf P, Baud D, Marshall SE, Munder M, Mosley A, et al. (2007) Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur J Immunol 37: 935-945.
29. Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, et al. (2001) Differential regulation of nitric oxide synthase-2 and arginase-1 by type1/type2 cytokines in vivo: Granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol 167: 6533-6544.
30. Vincendeau P, Gobert AP, Daulouede S, Moynet D, Mossalayi MD, (2003) Arginases in parasitic diseases. Trends in Parasitology 19: 9-12.
31. Zea AH, Culotta KS, Ali J, Mason C, Park HJ, et al. (2006) Decreased Expression of CD3 zeta and Nuclear Transcription Factor kappa B in Patients with Pulmonary Tuberculosis: Potential Mechanisms and Reversibility with Treatment. J Infect Dis 194: 1385-1393.
32. Kropf P, Fuentes JM, Fahnrich E, Arpa L, Herath S, et al. (2005) Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. Faseb J 19: 1000-1002.
33. Modolell M, Choi B-S, Ryan RO, Hancock M, Titus RG, et al. (2009) Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Neglected Tropical Diseases 14: e480.
34. Das A, Hoare M, Davies N, Lopes AR, Dunn C, et al. (2008) Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 205: 2111-2124.
35. Cloke T, Garvery L, Choi BS, Abebe T, Hailu A, et al. (2010) Increased arginase activity correlates with disease severity in HIV seropositive patients. Journal of Infectious Diseases 202: 374-385.
36. Schmielau J, Finn OJ, (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61: 4756-4760.
37. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, et al. (2010) A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 184: 3284-3297.
38. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, et al. (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69: 1553-1560.
39. Muller I, Hailu A, Choi BS, Abebe T, Fuentes JM, et al. (2008) Age-related alteration of arginase activity impacts on severity of leishmaniasis. PLoS Negl Trop Dis 2: e235.
40. Choi BS, Martinez-Falero IC, Corset C, Munder M, Modolell M, et al. (2009) Differential impact of L-arginine deprivation on the activation and effector functions of T cells and macrophages. J Leukoc Biol 85: 268-277.
41. Kropf P, Bickle Q, Klemenz R, Müller I, (2002) Organ-specific distribution of CD4+T1/ST2+Th2 cells in Leishmania major infection. Eur J Immunol 32: 2450-2459.
42. Kropf P, Freudenberg N, Kalis C, Modolell M, Herath S, et al. (2004) Infection of C57BL/10ScCr and C57BL/10ScNCr mice with Leishmania major reveals a role for Toll-like receptor 4 in the control of parasite replication. J Leuk Biol 76: 48-57.
43. Nilsen R, Mshana RN, (1987) In situ characterization of the cutaneous immune response in Ethiopian cutaneous leishmaniasis. Scand J Immunol 26: 503-512.
44. Barral A, Jesus AR, Almeida RP, Carvalho EM, Barral-Netto M, et al. (1987) Evaluation of T-cell subsets in the lesion infiltrates of human cutaneous and mucocutaneous leishmaniasis. Parasite Immunol 9: 487-497.
45. Iniesta V, Gomez-Nieto, Corraliza I, (2001) The inhibition of Arginase by Nw-Hydroxy-L-Arginine controls the growths of Leishmania inside macrophages. J Exp Med 193: 777-783.
46. Peters NC, Sacks DL, (2009) The impact of vector-mediated neutrophil recruitment on cutaneous leishmaniasis. Cell Microbiol 11: 1290-1296.
47. Charmoy M, Auderset F, Allenbach C, Tacchini-Cottier F, (2010) The prominent role of neutrophils during the initial phase of infection by Leishmania parasites. J Biomed Biotechnol 2010: 719361.
48. Rizk M, Witte MB, Barbul A, (2004) Nitric oxide and wound healing. World J Surg 28: 301-306.
49. Wu G, Bazer FW, Davis TA, Kim SW, Li P, et al. (2009) Arginine metabolism and nutrition in growth, health and disease. Amino Acids 37: 153-168.
50. Debats IB, Wolfs TG, Gotoh T, Cleutjens JP, Peutz-Kootstra CJ, et al. (2009) Role of arginine in superficial wound healing in man. Nitric Oxide 21: 175-183.
51. Abeyakirthi S, Mowbray M, Bredenkamp N, van Overloop L, Declercq L, et al. (2010) Arginase is overactive in psoriatic skin. Br J Dermatol 163: 193-196.
52. Bruch-Gerharz D, Schnorr O, Suschek C, Beck K-F, Pfeilschnifter J, et al. (2003) Arginase 1 overexpression in psoriasis. Am J Pathol 162: 203-211.
53. Jude EB, Boulton AJ, Ferguson MW, Appleton I, (1999) The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor beta 1. Diabetologia 42: 748-757.
54. Mori M, (2007) Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J Nutr 137: 1616S-1620S.
55. Kavalukas SL, Uzgare AR, Bivalacqua TJ, Barbul A, (2011) Arginase inhibition promotes wound healing in mice. Surgery 151: 287-295.
56. Popovic PJ, Zeh HJ 3rd, Ochoa JB, (2007) Arginine and immunity. J Nutr 137: 1681S-1686S.
57. Munder M, Choi B-S, Rogers M, Kropf P, (2009) L-arginine deprivation impairs Leishmania major-specific T cell responses. European Journal of Immunology 39: 2161-2172.
58. Munder M, Schneider H, Luckner C, Giese T, Langhans CD, et al. (2006) Suppression of T cell functions by human granulocyte arginase. Blood 108: 1627-1634.
59. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta JQ, et al. (2003) L-arginine consumption by macrophages modulates the expression of CD3z chain in T lymphocytes. J Immunol 171: 1232-1239.
60. Moulian N, Bidault J, Planche C, Berrih-Aknin S, (1998) Two signaling pathways can increase fas expression in human thymocytes. Blood 92: 1297-1307.
61. Weyand CM, Goronzy J, Fathman CG, (1987) Modulation of CD4 by antigenic activation. J Immunol 138: 1351-1354.
62. Bern C, Maguire JH, Alvar J, (2008) Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2: e313.